… on the clinical utility of biomarkers as pre-treatment predictors for tumor recurrence and as
… current biomarkers in HCC with respect to their clinical utility in surveillance, early diagnosis, …

… [7] first described the clinical feasibility of such software programs. They analyzed 15 liver
tumors and found that the sensitivity of software-assisted detection of tumor feeders was 89%. …

… liver tumors such as small cavernous hemangiomas and cysts that do not require treatment
(4,5). Several studies have reported that the bolus administration of extracellular fluid (ECF) …

… -1 are the first novel tumor biological prognostic factors that have been validated at the highest
level of evidence (to be discussed later) with regard to their clinical utility in breast cancer. …

… with synchronous or metachronous liver metastases, metastatic disease confined to the liver,
and radical surgery for liver metastases (as well as primary tumors if synchronic) performed …

… Hemangiomas are very common liver tumors that occur in about 7% of the … liver tumors may
be evident from the evaluation of the histologic findings in the normal liver and in liver tumors…

… This article provides an overview of the clinical utility of current biomarkers of HCC in
surveillance and early diagnosis. The controversy of using biomarkers in these settings is …

… There are many approaches available for preoperative imaging of liver tumors.
Transabdominal ultrasound is noninvasive, fast, the least expensive, and the modality of choice to …

… In our study, however, no significant differences were observed in tumor type or underlying
liver conditions between the biopsy succeeded and biopsy failed patients. We suppose that …

… the clinical utility of the three most commonly used biomarkers: AFP, PIVKA-II and AFP-L3,
and discuss the combinations of these three biomarkers with other clinical variables to …